If you have obstructive sleep apnoea and you're carrying excess weight, you've probably been told some version of "lose weight and your sleep apnoea will improve." Easy advice to give. Brutally difficult advice to follow when your sleep disorder is simultaneously making weight loss harder by disrupting the hormones that regulate appetite and metabolism.
GLP-1 medications may have broken that cycle. And in late 2025, tirzepatide (Mounjaro/Zepbound) became the first GLP-1 medication with a specific FDA approval for treating obstructive sleep apnoea in adults with obesity.
The connection between weight and sleep apnoea
Obstructive sleep apnoea (OSA) occurs when the tissues in the upper airway collapse during sleep, blocking normal breathing. Excess weight — particularly fat deposits around the neck, tongue, and upper airway — is the single biggest modifiable risk factor.
Approximately 60-70% of people with OSA are overweight or obese. And the relationship is dose-dependent: the more excess weight, the more severe the apnoea tends to be. Even moderate weight loss (10-15%) can significantly reduce the severity of OSA, and in some cases resolve it entirely.
The problem is that OSA itself makes weight loss harder. Fragmented sleep disrupts ghrelin and leptin (the hunger and satiety hormones), increases cortisol, reduces energy for exercise, and promotes insulin resistance. It's a vicious cycle that willpower alone rarely breaks.
The tirzepatide data
The SURMOUNT-OSA trials specifically evaluated tirzepatide in adults with moderate-to-severe obstructive sleep apnoea and obesity. The results led to FDA approval for this indication in 2025.
Participants receiving tirzepatide showed significant reductions in the apnoea-hypopnoea index (AHI) — the standard measure of sleep apnoea severity, counting the number of breathing interruptions per hour of sleep. Many participants moved from severe to moderate, moderate to mild, or mild to resolved categories.
The improvements were driven primarily by weight loss reducing the physical obstruction of the airway, but GLP-1 receptor activation may also have direct effects on respiratory drive and upper airway muscle tone — an area of active research.
Crucially, the trial evaluated participants both with and without CPAP therapy. The benefits were additive: tirzepatide improved OSA in people already using CPAP, and also helped people who couldn't tolerate CPAP.
What about semaglutide?
Semaglutide doesn't have a specific FDA indication for sleep apnoea, but the evidence suggests comparable benefits through the same mechanism — weight loss reducing airway obstruction.
The SELECT trial, which studied semaglutide 2.4mg in adults with obesity and cardiovascular disease, included sleep apnoea as a secondary outcome. Participants showed significant improvements in sleep-disordered breathing metrics (Lincoff et al., 2023). With Wegovy HD producing 20.7% weight loss — comparable to tirzepatide — the sleep apnoea benefits at the highest semaglutide doses are likely similar.
Multiple real-world studies and case series have documented significant CPAP pressure reductions and, in some patients, the ability to discontinue CPAP entirely after achieving sufficient weight loss on GLP-1 medications. However, formal semaglutide-specific OSA trials matching the SURMOUNT-OSA design have not been completed.
Can you ditch the CPAP?
This is the question everyone with sleep apnoea wants answered. And the honest answer is: maybe, but not yet, and not without proper medical evaluation.
Some people on GLP-1 medications lose enough weight that their AHI drops below the threshold for clinically significant sleep apnoea. In these cases, their sleep medicine doctor may determine that CPAP is no longer necessary.
But you should never stop CPAP on your own based on feeling better or losing weight. Sleep apnoea can persist even after significant weight loss due to structural factors (jaw anatomy, tonsil size, nasal obstruction) that aren't affected by weight. The only way to know if your apnoea has resolved is a follow-up sleep study (polysomnography or home sleep test).
What's more realistic for most people: GLP-1 medications reduce the severity of your apnoea, which may allow lower CPAP pressures, better CPAP tolerance, and improved sleep quality — even if you still need the machine.
A practical timeline:
- Start GLP-1 medication and continue CPAP as prescribed
- After 6-12 months of significant weight loss (~15%+ of body weight), discuss a repeat sleep study with your sleep medicine doctor
- Based on updated AHI results, your doctor may reduce CPAP pressure, switch to an oral appliance, or — in some cases — recommend discontinuing treatment
- Continue monitoring, because weight regain (if the GLP-1 is stopped) can bring the apnoea back
The energy cascade
Here's what makes the GLP-1/sleep apnoea combination particularly powerful: it creates a positive feedback loop.
Better sleep → more energy → more capacity for exercise → better weight loss → further improvement in sleep apnoea → even better sleep.
Many GLP-1 users with sleep apnoea report that the improvement in sleep quality is one of the first benefits they notice — sometimes before dramatic weight loss has occurred. Reduced inflammation and improved metabolic function may contribute to this early improvement.
The contrast with the pre-treatment vicious cycle is striking. Where untreated OSA plus obesity creates a downward spiral, treated OSA plus GLP-1-mediated weight loss creates an upward one.
Which medication to choose for sleep apnoea
Tirzepatide (Mounjaro/Zepbound) has the specific FDA indication and the dedicated clinical trial data for OSA. If sleep apnoea is a primary treatment concern, this gives tirzepatide the strongest evidence-based position.
Semaglutide (Ozempic/Wegovy) produces substantial weight loss that likely confers similar benefits, especially at the 7.2mg Wegovy HD dose. If you're already on semaglutide and your sleep apnoea is improving, there's no clear reason to switch. The cardiovascular protection data (SELECT trial) is also relevant, since OSA significantly increases cardiovascular risk.
Cost consideration: Generic semaglutide is on the horizon following patent expiry. Tirzepatide remains patent-protected. If long-term affordability matters and the sleep apnoea improvement is comparable, semaglutide's cost trajectory is more favourable.
Talk to your sleep medicine doctor
If you have both obesity and sleep apnoea, a GLP-1 medication should be part of the conversation. But ideally, it's a conversation that involves both your prescribing doctor (GP, endocrinologist, or obesity specialist) and your sleep medicine specialist. They can coordinate treatment, plan appropriate follow-up sleep studies, and adjust CPAP settings as your weight changes.
Sleep apnoea is a serious condition with real cardiovascular and cognitive consequences. GLP-1 medications are a powerful tool for improving it — potentially the most powerful pharmacological tool we've ever had for this condition — but they work best within a coordinated care framework.
Key Studies & References
-
Lincoff et al. (2023) — The SELECT trial evaluating semaglutide 2.4mg in adults with obesity and cardiovascular disease, which included sleep-disordered breathing improvements as a secondary outcome. Read the full study
-
Wilding et al. (2021) — The STEP 1 trial establishing semaglutide's weight-loss efficacy (~15%), the degree of weight loss consistently associated with meaningful OSA improvement. Read the full study
-
Wharton et al. (2025) — The STEP UP trial showing semaglutide 7.2mg achieved 20.7% weight loss — the level of reduction most likely to produce clinically significant OSA improvement or resolution. Read the full study
-
Jastreboff et al. (2022) — The SURMOUNT-1 trial demonstrating tirzepatide's 22.5% weight loss, providing context for the weight-loss-driven mechanism behind tirzepatide's OSA approval. Read the full study